{
  "id": 628697,
  "title": "Celltrion Tops 90% Of Omlyclo Market",
  "url": "https://urgent.news/2026/08/12/celltrion-tops-90-of-omlyclo-market",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-12T04:12:52.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=274641"
  },
  "original_language": "en",
  "account": "Celltrion is experiencing a significant surge in its market share with the autoimmune disease treatment 'Omlyclo', surpassing 90% in Spain as of June. The company's subsidiary in Spain was chosen as the supplier for the provincial government bids in four regions, including Catalonia, Basque Country, Asturias, and Valencia. This victory came after Omlyclo gained market acceptance as a treatment for chronic spontaneous urticaria and allergic asthma.\n\nThe key factor in Omlyclo's success has been its innovative 150mg autoinjector formulation, which is absent in the original product. Additionally, Omlyclo has demonstrated a relatively long shelf life and room temperature stability. To bolster its sales efforts, Celltrion is focusing on local medical professionals and pharmacy officials, highlighting the medical cost reduction benefits that arise from transitioning to biosimilars.\n\nIngesa, a bidding agency affiliated with the Spanish Ministry of Health, has also awarded Omlyclo and its counterpart 'Aptozma' in consecutive bids. Aptozma has now reached a majority market share in Spain as of the second quarter. Celltrion's sales strategy for Aptozma includes launching a 400mg formulation, which differentiates it from the original product.\n\nPortugal is also witnessing similar success for Celltrion's autoimmune disease treatments. In the first half of the year, all autoimmune disease treatment products, including Remsima, Yuflyma, and Steqeyma, were awarded in the national bidding. Moreover, Omlyclo and the ophthalmic disease treatment Eydenzelt were listed among the successful bidders. Celltrion's head in Spain, Kang Seok-hoon, anticipates that sales growth will accelerate further from the second half of the year, following the commencement of full-scale product supply and ongoing bidding successes for new products.",
  "summary": "Celltrion is rapidly expanding its market influence by successfully securing large-scale bids in major European countries, Spain and Portugal.In Spain, one of the top five major European countries, the treatment for chronic spontaneous urticaria and allergic asthma ‘Omlyclo’ successfully settled int",
  "key_points": [
    "Celltrion's Omlyclo dominates 90% of the Spanish market as of June.",
    "Innovative 150mg autoinjector formulation key to Omlyclo's success.",
    "Celltrion targeting local medical professionals to promote Omlyclo."
  ],
  "editors_take": "Celltrion's dominance in Spain's Omlyclo market solidifies its position as a biosimilar supplier, driven by the product's innovative formulation, long shelf life, and cost reduction benefits for medical professionals.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}